Fritsch, K., Kasenda, B., Schorb, E., Hau, P., Bloehdorn, J., Moehle, R., Loew, S., Binder, M., Atta, J., Keller, U., Wolf, H-H, Krause, S. W., Hess, G., Naumann, R., Sasse, S., Hirt, C., Lamprecht, M., Martens, U., Morgner, A., Panse, J., Frickhofen, N., Roeth, A., Hader, C., Deckert, M., Fricker, H., Ihorst, G., Finke, J. and Illerhaus, G. (2017). High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 31 (4). S. 846 - 853. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Full text not available from this repository.

Abstract

To investigate immuno-chemotherapy for elderly immuno-competent patients (. 65 years) with newly diagnosed primary central nervous system lymphoma, we conducted a multicentre single-arm trial. One cycle consisted of rituximab (375 mg/m(2), days 1, 15, 29), high-dose methotrexate (3 g/m(2) days 2, 16, 30), procarbazine (60 mg/m(2) days 2-11) and lomustine (110 mg/m(2), day 2)-R-MPL protocol. Owing to infectious complications, we omitted lomustine during the study and consecutive patients were treated with the R-MP protocol. Three cycles were scheduled and repeated on day 43. Subsequently, patients commenced 4 weekly maintenance treatment with procarbazine (100 mg for 5 days). Primary end point was complete remission (CR) after 3 cycles. We included 107 patients (69 treated with R-MPL and 38 with R-MP). In all, 38/107 patients achieved CR (35.5%) and 15 (14.0%) achieved partial remission. R-MP was associated with a lower CR rate (31.6%) compared with R-MPL (37.7%), but respective 2-year progression-free survival (All 37.3%; R-MP 34.9%; R-MPL 38.8%) and overall survival (All 47.0%; R-MP 47.7%; R-MPL 46.0%) rates were similar. R-MP was associated with less. grade 3 toxicities compared with R-MPL (71.1% vs 87.0%). R-MP is more feasible while still associated with similar efficacy compared with R-MPL and warrants further improvement in future studies.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Fritsch, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kasenda, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schorb, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hau, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bloehdorn, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Moehle, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Loew, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Binder, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Atta, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Keller, U.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, H-HUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krause, S. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hess, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Naumann, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sasse, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hirt, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lamprecht, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Martens, U.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Morgner, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Panse, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Frickhofen, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roeth, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hader, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Deckert, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fricker, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ihorst, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Finke, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Illerhaus, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-236040
DOI: 10.1038/leu.2016.334
Journal or Publication Title: Leukemia
Volume: 31
Number: 4
Page Range: S. 846 - 853
Date: 2017
Publisher: NATURE PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 1476-5551
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
NERVOUS-SYSTEM LYMPHOMA; PHASE-II; EUROPEAN-ORGANIZATION; PROCARBAZINE; RITUXIMAB; RADIOTHERAPY; TEMOZOLOMIDE; POPULATION; CYTARABINE; TRIALSMultiple languages
Oncology; HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/23604

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item